PF-04929113 (also known as SNX-5422 or PF04929113/SNX5422, CAS: 908115-27-5) is a small molecule inhibitor of heat shock protein 90 (Hsp90), a chaperone protein that is involved in the folding and stabilization of various client proteins, including many oncogenic signaling proteins. It has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of solid tumors.
Chemical name: N-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholinophenyl)-1H-pyrazole-3-carboxamide
Molecular formula: C23H28N4O4
Formula weight: 428.5 g/mol
CAS No: 908115-27-5
Top ten keywords from Google:
Health benefits of this product: PF-04929113 has demonstrated potential health benefits in the area of cancer research, particularly in the treatment of solid tumors. Its primary mode of action is through inhibition of Hsp90, leading to destabilization and degradation of various oncogenic signaling proteins.
Potential effects: PF-04929113 has demonstrated efficacy in several preclinical and clinical studies in inhibiting the activity of Hsp90, leading to destabilization and degradation of various oncogenic signaling proteins. It also has potential benefits for inducing apoptosis (programmed cell death), reducing angiogenesis (the formation of new blood vessels that can support tumor growth), and enhancing the immune response to cancer cells. PF-04929113 works by disrupting various cellular processes that are necessary for cancer cell survival and growth.
Product mechanism: PF-04929113 works by inhibiting the activity of Hsp90, which is a chaperone protein involved in the folding and stabilization of various client proteins, including many oncogenic signaling proteins. By inhibiting Hsp90, PF-04929113 can destabilize and degrade these signaling proteins, leading to reduced tumor growth and increased apoptosis.
Safety: PF-04929113 has been evaluated in several preclinical and clinical trials involving hundreds of participants and has been generally well-tolerated. Common side effects may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, as well as hematological abnormalities (e.g., decreased white blood cell or platelet counts) and hepatic dysfunction. Patients with liver or kidney disease should exercise caution when taking PF-04929113, as it may affect these conditions. Pregnant or breastfeeding women should avoid using PF-04929113, as its safety in these populations has not been established.
Side effects: Less common but more severe side effects of PF-04929113 may include bleeding disorders, cardiovascular events, and liver or kidney dysfunction, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The optimal dose and dosing regimen of PF-04929113 may vary depending on the patient's condition and treatment goals. In preclinical studies, doses ranging from 10 to 200 mg have been evaluated for various types of cancer. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: PF-04929113 (SNX-5422 or PF04929113/SNX5422, CAS: 908115-27-5) is a small molecule inhibitor of Hsp90, a chaperone protein involved in the folding and stabilization of various client proteins, including many oncogenic signaling proteins. It has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of solid tumors. Although it has been generally well-tolerated in preclinical and clinical trials, it may cause some side effects that should be monitored closely. More research is needed to determine its full potential and efficacy in different patient populations and cancer types. PF-04929113 offers a promising avenue for treatment of cancer by destabilizing oncogenic signaling proteins and inhibiting tumor growth.